Peptides DB
Research-centric peptide and protocol reference hub

Pasireotide record · updated 16h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 30 studiesJump to the evidenceCompare
What is Pasireotide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: Somatostatin receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Pasireotide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 80 registered trials. It describes the research record, not a recommendation.

Identity
NamePasireotide
Chain length—
Molecular weight1,047.2 Da
FormulaC58H66N10O9
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 9941444. No verified residue count for this compound.

Pharmacology
MechanismSomatostatin receptor agonist
RouteSubcutaneous injection
Half-life~12 hours
Time to peak~24 hours
Duration~28 days
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Nov 7, 2026. How this works →
Research stats
Total studies30
Human / animal / cellular17 / 1 / 3
Highest trial phasePhase 4
Years covered2023–2026
Latest study17h ago
Publication history
20232026
Research funding
6 NIH projects · $775k awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports563
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

30 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Impact of perioperative corticosteroids on postoperative morbidity after pancreaticoduodenectomy: A systematic review, meta-analysis, and trial sequential analysis.
FindingClinically relevant postoperative pancreatic fistula was significantly reduced with corticosteroids (primary analysis: risk difference, -0.09; 95% confidence interval, -0.17 to -0.01; number needed to treat, 11).
review2026Full text read0.80
Recurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.
FindingNot reported in abstract.
Human2026Full text read0.80
Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.
FindingMedian follow-up of 3.3 years (range 0.5 to 5.9).
Human2026Full text read0.80
Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.
FindingNo significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).
In vitro2023Full text read0.80
Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.
FindingNo significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).
In vitro2026Full text read0.80
Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.
Finding80% of patients achieved hormonal control with biomarker-guided treatment.
review2026Full text read0.70
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
FindingHbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.
Human2026Full text read0.70
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
FindingHbA1c decreased from 7.7% to 6.3%.
Human2026Full text read0.70
Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.
FindingNot reported in abstract.
Human2023Full text read0.80
Fourteen-year bridge to cure in occult ectopic ACTH syndrome: resection of a 3-mm pulmonary carcinoid.
FindingNot reported in abstract.
Human2026Full text read0.80
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial.
Finding6.2% (1.6%) of days with symptom exacerbations after switching to paltusotine, n=22, p<0.0001.
Human2026Full text read0.80
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.
FindingElimination half-life (t<sub>1/2</sub>) was 24-28 h.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Pasireotide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Pasireotide is discussed should be drawn from it.

Articles mentioning Pasireotide